APEX1 and chronic myelomonocytic leukemia: The combination of PARP inhibitor and APE1 inhibitor may be a candidate treatment for malignant hematological tumors, such as myelodysplastic syndromes/chronic myelomonocytic leukemia and acute myeloid leukemia.